Ernexa Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ERNA research report →
Price Chart
About the company
Ernexa Therapeutics Inc. is a biotechnology firm currently in its preclinical development phase, specializing in the creation of therapeutic interventions using induced mesenchymal stem cells (iMSCs). The company's primary focus lies in addressing solid tumor cancers and a range of autoimmune diseases.
- CEO
- Sanjeev Luther
- IPO
- 1991
- Employees
- 5
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on ERNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.42M
- P/E
- -0.24
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.67
- EV/EBITDA
- 0.19
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -305.85%
- ROIC
- -328.05%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-9,319,000
- Net Income
- $-14,084,000+68.4%
- EPS
- $-56.00-42.7%
- OCF Growth
- +55.7%
- FCF Growth
- +56.5%
- 52W High
- $71.50
- 52W Low
- $3.18
- 50D MA
- $5.34
- 200D MA
- $15.25
- Beta
- 2.56
- RSI (14)
- 48
- Avg Volume
- 484.33K
No earnings-call transcripts are available for ERNA yet.
- Free Float
- 31.8%
- Shares Outstanding
- 314.12K
- Float Shares
- 99.80K
of shares held by institutions
14 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 35.92K | ▲ 24.77K |
Held by 4 ETFs
Biggest fund positions in ERNA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 10, 26 | Cherington Charles | buy | 4,000,000 |
| Feb 10, 26 | Cherington Charles | buy | 4,000,000 |
| Jun 21, 25 | Gurrola Sandra M | other | 30 |
| Jun 21, 25 | Gurrola Sandra M | other | 30 |
| Jun 9, 25 | Cherington Charles | buy | 21,241,163 |
| Sep 24, 24 | Cherington Charles | buy | 1,562,988 |
| Sep 24, 24 | Cherington Charles | buy | 5,420,823 |
| Sep 24, 24 | Cherington Charles | buy | 1,237,762 |
| Sep 24, 24 | Cherington Charles | buy | 4,768,783 |
| Sep 24, 24 | Cherington Charles | buy | 261,756 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ERNA coverage
Recent articles, reports, and earnings notes.
No research on ERNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ERNA report →Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage
globenewswire.com · Aug 10
Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
globenewswire.com · Jul 24
Ernexa Therapeutics Stock Climbs After Independent Study Validates ERNA-101 Tumor-Fighting Cell Therapy
benzinga.com · Jul 15
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
globenewswire.com · Jul 15
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
globenewswire.com · Jul 14
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
globenewswire.com · Jul 14
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
globenewswire.com · Jun 25
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
globenewswire.com · Jun 17
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.